Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Stephen Bagley, MD, MSCE
With
Primary Objective: • To determine the efficacy of abemaciclib for recurrent oligodendroglioma, as measured by the estimated proportion of patients alive without disease progression at 6 months from study enrollment (PFS-6) Secondary Objectives: * To evaluate the safety and tolerability of abemaciclib in recurrent oligodendroglioma * To estimate the objective radiographic response rate (ORR) associated with abemaciclib in recurrent oligodendroglioma * To determine the median progression-free survival (PFS) and overall survival (OS) of patients with recurrent oligodendroglioma treated with abemaciclib * To determine ORR, PFS, and OS in the subgroup of recurrent oligodendroglioma patients with tumor CIC gene mutations Exploratory Objectives: * To measure pharmacodynamic markers of abemaciclib activity on oligodendroglial tumor cells * To identify pre-treatment tumor characteristics that are associated with response to abemaciclib recurrent oligodendroglioma
Age
18–any
Sex
ALL
Healthy volunteers
Accepted